Medical News

Treatment with the investigational therapy RNS60 (Revalesio, Tacoma, WA) was associated with a significant reduction in infarct growth and clinically meaningful improvements for individuals with acute ischemic stroke (AIS) treated within 12 hours of symptom onset. These results were presented at the...

Results of the ESCAPE-MeVO (NCT05151172) and DISTAL (NCT05029414) clinical trials demonstrated that endovascular treatment (EVT) plus medical treatment did not lead to better outcomes vs medical treatment alone in individuals with stroke caused by medium vessel occlusion (MVO) or distal vessel occlu...

The American Stroke Association (ASA) recognized 11 award recipients at the International Stroke Conference 2025. The awards honor the exceptional contributions and professional achievements of leaders in the field of stroke, recognizing accomplishments across research, clinical care, and service.

Treatment with propranolol for women with migraine may reduce risk of stroke, according to findings from a preliminary study of 3 million electronic health records (EHRs) presented at the American Stroke Association’s International Stroke Conference 2025. Propranolol, a nonselective beta-blocker pre...

The Food and Drug Administration (FDA) has approved the wearable Onapgo (apomorphine hydrochloride; Supernus Pharmaceuticals, Rockville, MD) subcutaneous injection device to treat motor fluctuations in adults with advanced Parkinson disease (PD). Onapgo enables continuous apomorphine infusion during...

The American Headache Society (AHS) is currently accepting applications for multiple scholarship and abstract award opportunities. Recipients will receive complimentary registration for the 67th Annual Scientific Meeting of the AHS in Minneapolis, MN, where abstract award winners will have the oppor...

Journavx (suzetrigine; Vertex Pharmaceuticals, Boston, MA) has received approval from the Food and Drug Administration (FDA) for the treatment of adults with moderate-to-severe acute pain. Journavx is an oral, non-opioid, selective inhibitor of Na_v1.8, which is a voltage-gated sodium channel that pl...

The Food and Drug Administration (FDA) has approved Symbravo (meloxicam and rizatriptan; Axsome Therapeutics, New York, NY) for the acute treatment of adults diagnosed with migraine with or without aura. Symbravo, previously known as AXS-07, is a single-dose, oral medication for use as-needed. Axsom...

Researchers have identified 8 alternative and off-label treatments (AOTs) which may have efficacy for targeting some of the multiple, overlapping pathogenic mechanisms thought to underly amyotrophic lateral sclerosis (ALS), such as neuroinflammation, oxidative stress, mitochondrial dysfunction, micr...

Treatment with intra-arterial TNKase (tenecteplase; Genentech, South San Francisco, CA) after successful endovascular thrombectomy (EVT) for people with acute ischemic stroke (AIS) due to large vessel occlusion did not significantly increase the likelihood of freedom from disability. The results of ...

The emergence of new biomarker tests may enable earlier detection and treatment of symptoms associated with synucleinopathies according to a new comprehensive Clinical Proceedings White Paper published by the Clinical Neurological Society of America (CNSA).

The White Paper, titled “Minimizing the D...

The Food and Drug Administration (FDA) has approved the Supplemental Biologics License Application (sBLA) for maintenance dosing with Leqembi (lecanemab-irmb; Eisai, Tokyo, Japan; Biogen, Cambridge, MA). The approval enables patients with early Alzheimer disease (AD) to receive Leqembi treatment by ...

The Food and Drug Administration (FDA) has added a Boxed Warning to the prescribing information of glatiramer acetate, a medication for multiple sclerosis (MS) sold under the brand name Copaxone (glatiramer acetate injection; Teva, Tel Aviv-Yafo, Israel) and the generic name Glatopa (glatiramer acet...

The Food and Drug Administration (FDA) has granted Priority Review designation to the Biologics License Application (BLA) for nipocalimab (Johnson & Johnson, New Brunswick, NJ) for the treatment of people with generalized myasthenia gravis (gMG) who are antibody positive, including anti-acetylcholin...

Recommendations for a standardized nomenclature to improve interdisciplinary communication for peripheral nervous system (PNS) disorders across rheumatology and neurology were published in Arthritis & Rheumatology, the journal of the American College of Rheumatology. The recommendations specifically...

A retrospective chart review published in the Journal of Alzheimer's Disease highlights gaps in diagnosing and managing early Alzheimer disease (AD) in US community-based practices. Researchers found that nearly 1 in 5 patients (16.1%) with early AD did not receive standard neurocognitive assessment...